Murdoch-backed REA sweetens offer for UK's Rightmove to nearly $7.9 billion, FT reports
Controversial North Carolina candidate for governor rattles Republicans in critical swing state
Federal authorities subpoena NYC mayor's director of asylum seeker operations
Biden opens busy foreign policy stretch as anxious allies shift gaze to Trump, Harris
New Zealand’s army chief: Pacific nations need tailored military training
Fed's Bowman says dissent on large rate cut based on above-target inflation data
Kenya court finds Meta can be sued over moderator layoffs
Widener University's Beyoncé course allows students to explore her influence on African-American culture
New York magazine says its star political reporter is on leave after a relationship was disclosed
Why Kelly Clarkson chooses a 'safe' interviewing approach. Her talk show kicks off its sixth season
Business|Europe|Finance|Health|Stock Markets
Novo Nordisk shares drop nearly 5% on disappointing obesity pill data
Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental
September 20, 2024